文献速递中枢神经肿瘤放疗姑息放疗与转移瘤放疗物理与技术

RAPPLE 靶向放疗对比全脑放疗:匹配后预后不良脑转移患者的回顾性队列研究

RAPid simPLE (RAPPLE) Targeted Radiation Treatment Versus Whole Brain Radiation Therapy: A Retrospective Cohort Study of Matched Patients With Brain Metastases and Poor Prognosis.
PubMed 文献 · Adv Radiat Oncol · 2026-03-28

本研究回顾性比较 RAPPLE(单等中心共面 VMAT,20 Gy/5 次)与全脑放疗在匹配后预后不良脑转移患者中的结局。RAPPLE 对正常脑组织的剂量保护程度与 SRS 相近,97% 患者避免了 WBRT。

要点

  • RAPPLE 正常脑组织受量接近 SRS,97% 患者避免 WBRT。

核心结论

  • 匹配后 RAPPLE 与 WBRT 组总生存无差异,但 RAPPLE 组颅内进展累积发生率更高。
  • RAPPLE 对正常脑组织的剂量保护程度与 SRS 相近,97% 患者避免了 WBRT。

研究设计与样本

  • 回顾性队列研究,从机构数据库纳入 2017 年 1 月 1 日至 2021 年 11 月 5 日首次接受 RAPPLE 的患者。
  • 按年龄、肿瘤诊断、脑转移数目和治疗日期进行 1:1 匹配 RAPPLE 与 WBRT 患者,共 248 例。
  • 另随机选取 10 例代表 1 至 10 个脑转移灶的病例,以 35 Gy/5 次 SRS 计划为对照,用 RAPPLE 重新计划比较脑减大体肿瘤体积平均剂量。

主要发现

  • 18 个月生存率 RAPPLE 11%(95%CI 7-19)、WBRT 12%(95%CI 8-19)。
  • RAPPLE 后 12% 接受更多局灶放疗,3% 需挽救性 WBRT;脑减大体肿瘤体积平均剂量 SRS 为 5.04 Gy、RAPPLE 为 4.31 Gy。

关键数值与推荐

  • RAPPLE 技术为单等中心共面 VMAT,靶向脑转移灶,剂量 20 Gy/5 次。
  • 对照 SRS 计划剂量为 35 Gy/5 次,用于比较脑减大体肿瘤体积平均剂量。
  • 匹配变量为年龄、肿瘤诊断、脑转移数目和治疗日期。

临床怎么用

  • 对预后不良、不适合 SRS 的脑转移患者,RAPPLE 可作为避免 WBRT 的备选方案。
  • 选择 RAPPLE 需权衡其较高的颅内进展累积发生率与正常脑组织保护及避免 WBRT 的获益。

局限性

  • 本研究为单中心回顾性队列研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with brain metastases whose poor prognosis does not warrant stereotactic radiosurgery (SRS) often receive whole brain radiation therapy (WBRT). We compared the outcomes of patients treated with a novel brain-sparing radiation therapy technique with those of matched patients treated with WBRT. METHODS AND MATERIALS: RAPid simPLE (RAPPLE) uses single-isocenter, coplanar volumetric modulated arc therapy to target brain metastases with 20 Gy in 5 fractions. Patients treated with a first course of RAPPLE between January 1, 2017, and November 5, 2021, were identified in an institutional database. Using age, cancer diagnosis, number of brain metastases, and treatment date, we 1:1-matched patients who received RAPPLE and WBRT. Endpoints were overall survival, calculated using the Kaplan-Meier method, and cumulative incidence of intracranial progression with a competing risk of death. Log-rank, Gray's test, Cox regression, and Fine-Gray analyses were used for comparisons. Ten cases were randomly selected from an institutional database, each representing a unique lesion count from 1 to 10 brain metastases, and treated with 35Gy in 5 fractions using linear accelerator SRS. These were replanned using RAPPLE to compare the mean dose to the brain minus gross tumor volume. RESULTS: The study cohort comprised 248 patients. Median survival was 4.5 months for RAPPLE and 4.0 months for WBRT (log-rank P = .4), and 18-month survival was 11% (95% CI, 7-19) for RAPPLE and 12% (95% CI, 8-19) for WBRT. In multivariable analysis, using RAPPLE versus WBRT was not predictive of overall survival (hazard ratio, 0.82; 95% CI, 0.62-1.09; P = .2). The 18-month cumulative incidence of intracranial progression was 50% (95% CI, 41-59) for RAPPLE and 31% (95% CI, 23-40) for WBRT (Gray's test P = .002). After RAPPLE, 12% received more focal RT, and 3% required salvage WBRT. The mean dose to brain minus gross tumor volume was 5.04 Gy for SRS and 4.31 Gy for RAPPLE. CONCLUSIONS: There was no difference in survival between the matched groups. RAPPLE spares normal brain volume to a degree analogous to that seen with SRS. Among patients treated with RAPPLE, 97% avoided WBRT.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Parmar GS, Kong T, Musoke R, et al. RAPid simPLE (RAPPLE) Targeted Radiation Treatment Versus Whole Brain Radiation Therapy: A Retrospective Cohort Study of Matched Patients With Brain Metastases and Poor Prognosis. Adv Radiat Oncol. 2026. PMID: 42199528. doi:10.1016/j.adro.2026.102034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。